Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Capital Expenditures: 2016-2024

Historic Capital Expenditures for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Dec 2024 value amounting to $3.8 million.

  • Crinetics Pharmaceuticals' Capital Expenditures rose 63.45% to $863,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 68.88%. This contributed to the annual value of $3.8 million for FY2024, which is 18.00% down from last year.
  • Per Crinetics Pharmaceuticals' latest filing, its Capital Expenditures stood at $3.8 million for FY2024, which was down 18.00% from $4.7 million recorded in FY2023.
  • In the past 5 years, Crinetics Pharmaceuticals' Capital Expenditures ranged from a high of $4.7 million in FY2023 and a low of $186,000 during FY2020.
  • Over the past 3 years, Crinetics Pharmaceuticals' median Capital Expenditures value was $3.8 million (recorded in 2024), while the average stood at $3.4 million.
  • As far as peak fluctuations go, Crinetics Pharmaceuticals' Capital Expenditures crashed by 62.20% in 2020, and later soared by 279.82% in 2022.
  • Over the past 5 years, Crinetics Pharmaceuticals' Capital Expenditures (Yearly) stood at $186,000 in 2020, then soared by 134.41% to $436,000 in 2021, then surged by 279.82% to $1.7 million in 2022, then skyrocketed by 183.09% to $4.7 million in 2023, then fell by 18.00% to $3.8 million in 2024.